Myopic Choroidal Neovascularization

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2015-09-02
Clinical Trial Update: Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia [NA]
Clinical trial evaluating intravitreal pegaptanib for myopic choroidal neovascularization has been withdrawn.